Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial

Deborah M. Friedman, Carolina Llanos, Peter M. Izmirly, Brigit Brock, John Byron, Joshua Copel, Karen Cummiskey, Mary Anne Dooley, Jill Foley, Cornelia Graves, Colleen Hendershott, Richard Kates, Elena V. Komissarova, Michelle Miller, Emmanuelle Pare, Colin K L Phoon, Tracy Prosen, Dale Reisner, Eric Ruderman, Philip SamuelsJerry K. Yu, Mimi Y. Kim, Jill P. Buyon

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Objective. The recurrence rate of anti-SSA/Ro - associated congenital heart block (CHB) is 17%. Sustained reversal of third-degree block has never been achieved. Based on potential reduction of maternal autoantibody titers as well as fetal inflammatory responses, intravenous immunoglobulin (IVIG) was evaluated as preventive therapy for CHB. Methods. A multicenter, prospective, open-label study based on Simon's 2-stage optimal design was initiated. Enrollment criteria included the presence of anti-SSA/Ro antibodies in the mother, birth of a previous child with CHB/neonatal lupus rash, current treatment with ≤20 mg/day of prednisone, and

Original languageEnglish (US)
Pages (from-to)1138-1146
Number of pages9
JournalArthritis and Rheumatism
Volume62
Issue number4
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Intravenous Immunoglobulins
Fetus
Clinical Trials
Mothers
Prednisone
Exanthema
Autoantibodies
Therapeutics
Parturition
Recurrence
Congenital heart block

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block : Results of a multicenter, prospective, open-label clinical trial. / Friedman, Deborah M.; Llanos, Carolina; Izmirly, Peter M.; Brock, Brigit; Byron, John; Copel, Joshua; Cummiskey, Karen; Dooley, Mary Anne; Foley, Jill; Graves, Cornelia; Hendershott, Colleen; Kates, Richard; Komissarova, Elena V.; Miller, Michelle; Pare, Emmanuelle; Phoon, Colin K L; Prosen, Tracy; Reisner, Dale; Ruderman, Eric; Samuels, Philip; Yu, Jerry K.; Kim, Mimi Y.; Buyon, Jill P.

In: Arthritis and Rheumatism, Vol. 62, No. 4, 04.2010, p. 1138-1146.

Research output: Contribution to journalArticle

Friedman, DM, Llanos, C, Izmirly, PM, Brock, B, Byron, J, Copel, J, Cummiskey, K, Dooley, MA, Foley, J, Graves, C, Hendershott, C, Kates, R, Komissarova, EV, Miller, M, Pare, E, Phoon, CKL, Prosen, T, Reisner, D, Ruderman, E, Samuels, P, Yu, JK, Kim, MY & Buyon, JP 2010, 'Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial', Arthritis and Rheumatism, vol. 62, no. 4, pp. 1138-1146. https://doi.org/10.1002/art.27308
Friedman, Deborah M. ; Llanos, Carolina ; Izmirly, Peter M. ; Brock, Brigit ; Byron, John ; Copel, Joshua ; Cummiskey, Karen ; Dooley, Mary Anne ; Foley, Jill ; Graves, Cornelia ; Hendershott, Colleen ; Kates, Richard ; Komissarova, Elena V. ; Miller, Michelle ; Pare, Emmanuelle ; Phoon, Colin K L ; Prosen, Tracy ; Reisner, Dale ; Ruderman, Eric ; Samuels, Philip ; Yu, Jerry K. ; Kim, Mimi Y. ; Buyon, Jill P. / Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block : Results of a multicenter, prospective, open-label clinical trial. In: Arthritis and Rheumatism. 2010 ; Vol. 62, No. 4. pp. 1138-1146.
@article{7df5e54e132e46f8a66a5df65a2e501b,
title = "Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial",
abstract = "Objective. The recurrence rate of anti-SSA/Ro - associated congenital heart block (CHB) is 17{\%}. Sustained reversal of third-degree block has never been achieved. Based on potential reduction of maternal autoantibody titers as well as fetal inflammatory responses, intravenous immunoglobulin (IVIG) was evaluated as preventive therapy for CHB. Methods. A multicenter, prospective, open-label study based on Simon's 2-stage optimal design was initiated. Enrollment criteria included the presence of anti-SSA/Ro antibodies in the mother, birth of a previous child with CHB/neonatal lupus rash, current treatment with ≤20 mg/day of prednisone, and",
author = "Friedman, {Deborah M.} and Carolina Llanos and Izmirly, {Peter M.} and Brigit Brock and John Byron and Joshua Copel and Karen Cummiskey and Dooley, {Mary Anne} and Jill Foley and Cornelia Graves and Colleen Hendershott and Richard Kates and Komissarova, {Elena V.} and Michelle Miller and Emmanuelle Pare and Phoon, {Colin K L} and Tracy Prosen and Dale Reisner and Eric Ruderman and Philip Samuels and Yu, {Jerry K.} and Kim, {Mimi Y.} and Buyon, {Jill P.}",
year = "2010",
month = "4",
doi = "10.1002/art.27308",
language = "English (US)",
volume = "62",
pages = "1138--1146",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block

T2 - Results of a multicenter, prospective, open-label clinical trial

AU - Friedman, Deborah M.

AU - Llanos, Carolina

AU - Izmirly, Peter M.

AU - Brock, Brigit

AU - Byron, John

AU - Copel, Joshua

AU - Cummiskey, Karen

AU - Dooley, Mary Anne

AU - Foley, Jill

AU - Graves, Cornelia

AU - Hendershott, Colleen

AU - Kates, Richard

AU - Komissarova, Elena V.

AU - Miller, Michelle

AU - Pare, Emmanuelle

AU - Phoon, Colin K L

AU - Prosen, Tracy

AU - Reisner, Dale

AU - Ruderman, Eric

AU - Samuels, Philip

AU - Yu, Jerry K.

AU - Kim, Mimi Y.

AU - Buyon, Jill P.

PY - 2010/4

Y1 - 2010/4

N2 - Objective. The recurrence rate of anti-SSA/Ro - associated congenital heart block (CHB) is 17%. Sustained reversal of third-degree block has never been achieved. Based on potential reduction of maternal autoantibody titers as well as fetal inflammatory responses, intravenous immunoglobulin (IVIG) was evaluated as preventive therapy for CHB. Methods. A multicenter, prospective, open-label study based on Simon's 2-stage optimal design was initiated. Enrollment criteria included the presence of anti-SSA/Ro antibodies in the mother, birth of a previous child with CHB/neonatal lupus rash, current treatment with ≤20 mg/day of prednisone, and

AB - Objective. The recurrence rate of anti-SSA/Ro - associated congenital heart block (CHB) is 17%. Sustained reversal of third-degree block has never been achieved. Based on potential reduction of maternal autoantibody titers as well as fetal inflammatory responses, intravenous immunoglobulin (IVIG) was evaluated as preventive therapy for CHB. Methods. A multicenter, prospective, open-label study based on Simon's 2-stage optimal design was initiated. Enrollment criteria included the presence of anti-SSA/Ro antibodies in the mother, birth of a previous child with CHB/neonatal lupus rash, current treatment with ≤20 mg/day of prednisone, and

UR - http://www.scopus.com/inward/record.url?scp=77950538130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950538130&partnerID=8YFLogxK

U2 - 10.1002/art.27308

DO - 10.1002/art.27308

M3 - Article

C2 - 20391423

AN - SCOPUS:77950538130

VL - 62

SP - 1138

EP - 1146

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 4

ER -